Stability-indicating methods for the determination of disopyramide phosphate.

J AOAC Int

Cairo University, Faculty of Pharmacy, Analytical Chemistry Department, Kasr-El-Aini 11562, Cairo, Egypt.

Published: November 2006

AI Article Synopsis

Article Abstract

Four methods were developed for the determination of intact disopyramide phosphate in the presence of its degradation product. In the first and second methods, third-derivative spectrophotometry and first derivative of the ratio spectra were used. For the third-derivative spectrophotometric method, the peak amplitude was measured at 272 nm, while for the derivative ratio spectrophotometric method, disopyramide phosphate was determined by measuring the peak amplitude at 248 and 273 nm. Both methods were used for the determination of disopyramide phosphate in the concentration range 12.5-87.5 microg/mL, with corresponding mean recovery 100.8 +/- 0.7% for the first method and 99.9 +/- 0.7% and 99.6 +/- 0.7% for the second method at 248 and 273 nm, respectively. In the third method, an ion selective electrode (ISE) was fabricated using phosphotungstic acid as an anionic exchanger, PVC as the polymer matrix, and dibutylsebacate as a plasticizer. The ISE was used for the determination of disopyramide phosphate in pure powder form in the concentration range 10(-2)-10(-5) M. The slope was found to be 58.5 (mV/decade), and the average recovery was 99.9 +/- 1.6%. The fourth method depended on the quantitative densitometric determination of the drug in concentration range of 0.25-2.5 microg/spot using silica gel 60 F245 plates and ethyl acetate-chloroform-ammonium hydroxide (85 + 10 + 5, v/v/v) as the mobile phase, with corresponding mean accuracy of 100.3 +/- 1.1%. The 4 proposed methods were found to be specific for disopyramide phosphate in presence of up to 80% of its degradation product for the spectrophotometric methods, 90% of its degradation for the densitometric method, and 40% for the ISE method. The 4 proposed procedures were successfully applied for the determination of disopyramide phosphate in Norpace capsules. Statistical comparison between the results obtained by these methods and the official method of the drug was done, and no significant differences were found.

Download full-text PDF

Source

Publication Analysis

Top Keywords

disopyramide phosphate
28
determination disopyramide
16
concentration range
12
+/- 07%
12
method
9
methods determination
8
phosphate presence
8
degradation product
8
derivative ratio
8
spectrophotometric method
8

Similar Publications

Cadmium (Cd) accumulation in rice poses significant risks to human health. The Cd accumulation levels vary widely among cultivars and are strongly associated with the rhizosphere microecosystem. However, the underlying mechanisms remain poorly understood.

View Article and Find Full Text PDF

Background: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular outflow tract obstruction (LVOTO), leading to symptoms and adverse outcomes. Disopyramide, with its negative inotropic effects, is commonly used to reduce LVOTO in obstructive HCM (HOCM). This study evaluates the impact of disopyramide on functional capacity in HOCM patients.

View Article and Find Full Text PDF

Treatment options for hypertrophic obstructive cardiomyopathy: a patient-centric review.

Expert Rev Cardiovasc Ther

November 2024

Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', AORN dei Colli, Monaldi Hospital, Naples, Italy.

Article Synopsis
  • Hypertrophic cardiomyopathy (HCM) is a condition characterized by thickening of the heart's left ventricle walls, affecting 1 in 200-500 people, with 60% of cases being hereditary.
  • The review discusses various treatments for HCM, including medications (like beta-blockers and calcium channel blockers) and surgical options, along with the importance of personalized patient care in improving outcomes.
  • Future treatments, such as new drugs and gene therapies, are also highlighted, emphasizing the significance of tailoring management strategies to individual patient needs and preferences.
View Article and Find Full Text PDF

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

View Article and Find Full Text PDF

Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.

Cell Mol Life Sci

November 2024

School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.

Article Synopsis
  • Potassium channels from the human hERG gene are affected by various drugs, and this study specifically investigates the effects of chiral disopyramide, a Class Ia antiarrhythmic, on hERG currents in HEK 293 cells.* -
  • The findings show that the S(+) enantiomer of disopyramide is more potent at inhibiting hERG current compared to the R(-) form, with IC values of 3.9 µM and 12.9 µM respectively, and certain mutations in hERG alter these effects.* -
  • Molecular simulations indicate that the S(+) form binds more effectively to specific residues in the hERG channel, while the R(-)
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!